Literature DB >> 21443541

Insig2 is overexpressed in pancreatic cancer and its expression is induced by hypoxia.

Tadashi Kayashima1, Kohei Nakata, Kenoki Ohuchida, Junji Ueda, Kengo Shirahane, Hayato Fujita, Lin Cui, Kazuhiro Mizumoto, Masao Tanaka.   

Abstract

A hypoxic microenvironment is a characteristic feature of pancreatic cancer, and induces the expressions of various genes involved in malignant behaviors. Insulin-induced gene 2 (Insig2) has recently been shown to be correlated with cellular invasion in colon cancer. However, there have been no reports regarding its expression in pancreatic cancer. In this study, we evaluated Insig2 mRNA expression and the biological function of Insig2 in pancreatic cancer. We measured Insig2 mRNA expression in cultured pancreatic cancer cell lines and invasive ductal carcinoma (IDC) cells, normal pancreatic epithelial cells, and pancreatic intraepithelial neoplasia cells obtained by laser-capture microdissection. We also investigated the effects of Insig2-targeting siRNAs on the cell proliferation and cell invasion of pancreatic cancer cell lines. All pancreatic cancer cell lines expressed Insig2 mRNA. The PANC-1 and MIA PaCa-2 pancreatic cancer cell lines showed >2-fold higher Insig2 mRNA expression levels under hypoxic conditions (1% O2) than under normoxic conditions (21% O2 ). Cell proliferation was significantly decreased in SUIT-2 cells and cell invasion was significantly decreased in SUIT-2, Capan-2, and CFPAC-1 cells after transfection of the Insig2-targeting siRNAs. In analyses of microdissected cells, cells from IDC tissues expressed significantly higher levels of Insig2 mRNA than normal pancreatic cells (P < 0.001) and pancreatic intraepithelial neoplasia cells (P = 0.082). In analyses of IDC cells, the levels of Insig2 mRNA expression were significantly higher in late-stage patients than in early-stage patients. The present data suggest that Insig2 is associated with the malignant potential of pancreatic cancer under hypoxic conditions.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21443541     DOI: 10.1111/j.1349-7006.2011.01936.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

1.  Isolation, sequence characterization, and tissue transcription profiles of two novel buffalo genes: INSIG1 and INSIG2.

Authors:  Chunfeng Wu; Lixian Liu; Jinlong Huo; Dalin Li; Yueyun Yuan; Feng Yuan; Yongwang Miao
Journal:  Trop Anim Health Prod       Date:  2013-07-17       Impact factor: 1.559

2.  microRNAs targeting cellular cholesterol: implications for combating anticancer drug resistance.

Authors:  Bernice Monchusi; Mandeep Kaur
Journal:  Genes Cancer       Date:  2020

3.  A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patients.

Authors:  Xing Wei; Xiaochong Zhou; Yun Zhao; Yang He; Zhen Weng; Chunfang Xu
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

4.  Polymorphic variants INSIG2 rs6726538, HLA-DRB1 rs9272143, and GCNT1P5 rs7780883 contribute to the susceptibility of cervical cancer in the Bangladeshi women.

Authors:  Md Emtiaz Hasan; Maliha Matin; Md Enamul Haque; Md Abdul Aziz; Md Shalahuddin Millat; Mohammad Sarowar Uddin; Md Mizanur Rahman Moghal; Mohammad Safiqul Islam
Journal:  Cancer Med       Date:  2021-02-14       Impact factor: 4.452

5.  Whole blood transcriptomics and urinary metabolomics to define adaptive biochemical pathways of high-intensity exercise in 50-60 year old masters athletes.

Authors:  Kamalika Mukherjee; Brittany A Edgett; Harrison W Burrows; Cecilia Castro; Julian L Griffin; Adel Giaid Schwertani; Brendon J Gurd; Colin D Funk
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

6.  Novel therapies targeting hypoxia mechanism to treat pancreatic cancer.

Authors:  Wenhao Luo; Jiangdong Qiu; Lianfang Zheng; Taiping Zhang
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.